Literature DB >> 9069292

Androgen deprivation and radiation therapy in prostate cancer: the evolving case for combination therapy.

A L Zietman, W U Shipley.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9069292     DOI: 10.1016/s0360-3016(97)00122-3

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


× No keyword cloud information.
  5 in total

1.  What is appropriate neoadjuvant/adjuvant androgen deprivation for high-risk/locally advanced prostate cancer?

Authors:  Mikio Namiki; Hiroyuki Konaka
Journal:  Asian J Androl       Date:  2011-06-06       Impact factor: 3.285

Review 2.  Effectiveness and adverse effects of hormonal therapy for prostate cancer: Japanese experience and perspective.

Authors:  Mikio Namiki; Satoru Ueno; Yasuhide Kitagawa; Takashi Fukagai; Hideyuki Akaza
Journal:  Asian J Androl       Date:  2012-03-26       Impact factor: 3.285

3.  Tri-Modality therapy with I-125 brachytherapy, external beam radiation therapy, and short- or long-term hormone therapy for high-risk localized prostate cancer (TRIP): study protocol for a phase III, multicenter, randomized, controlled trial.

Authors:  Hiroyuki Konaka; Shin Egawa; Shiro Saito; Atsunori Yorozu; Hiroyuki Takahashi; Keiko Miyakoda; Masanori Fukushima; Takushi Dokiya; Hidetoshi Yamanaka; Nelson N Stone; Mikio Namiki
Journal:  BMC Cancer       Date:  2012-03-22       Impact factor: 4.430

Review 4.  Role of hormonal therapy for prostate cancer: perspective from Japanese experiences.

Authors:  Mikio Namiki; Satoru Ueno; Yasuhide Kitagawa
Journal:  Transl Androl Urol       Date:  2012-09

5.  Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer.

Authors:  Changping Wu; Xin Jin; Jing Yang; Yinhui Yang; Yundong He; Liya Ding; Yunqian Pan; Shuai Chen; Jingting Jiang; Haojie Huang
Journal:  Oncotarget       Date:  2016-01-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.